Loading...

biote Corp.

BTMDWPNK
Healthcare
Medical - Care Facilities
$1.61
$0.25(18.38%)
U.S. Market is Open • 13:13

biote Corp. Fundamental Analysis

biote Corp. (BTMDW) shows moderate financial fundamentals with a PE ratio of 2.38, profit margin of 14.07%, and ROE of -35.31%. The company generates $1.1B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position48.81%
PEG Ratio0.01

Areas of Concern

ROE-35.31%
We analyze BTMDW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 27.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
27.0/100

We analyze BTMDW's fundamental strength across five key dimensions:

Efficiency Score

Excellent

BTMDW demonstrates superior asset utilization.

ROA > 10%
25.13%

Valuation Score

Excellent

BTMDW trades at attractive valuation levels.

PE < 25
2.38
PEG Ratio < 2
0.01

Growth Score

Moderate

BTMDW shows steady but slowing expansion.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

BTMDW maintains a strong and stable balance sheet.

Debt/Equity < 1
-1.88
Current Ratio > 1
1.22

Profitability Score

Weak

BTMDW struggles to sustain strong margins.

ROE > 15%
-3530.97%
Net Margin ≥ 15%
14.07%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is BTMDW Expensive or Cheap?

P/E Ratio

BTMDW trades at 2.38 times earnings. This suggests potential undervaluation.

2.38

PEG Ratio

When adjusting for growth, BTMDW's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values biote Corp. at -1.10 times its book value. This may indicate undervaluation.

-1.10

EV/EBITDA

Enterprise value stands at 0.17 times EBITDA. This is generally considered low.

0.17

How Well Does BTMDW Make Money?

Net Profit Margin

For every $100 in sales, biote Corp. keeps $14.07 as profit after all expenses.

14.07%

Operating Margin

Core operations generate 18.50 in profit for every $100 in revenue, before interest and taxes.

18.50%

ROE

Management delivers $-35.31 in profit for every $100 of shareholder equity.

-35.31%

ROA

biote Corp. generates $25.13 in profit for every $100 in assets, demonstrating efficient asset deployment.

25.13%

Following the Money - Real Cash Generation

Operating Cash Flow

biote Corp. produces operating cash flow of $208.55M, showing steady but balanced cash generation.

$208.55M

Free Cash Flow

biote Corp. generates strong free cash flow of $177.70M, providing ample flexibility for dividends, buybacks, or growth.

$177.70M

FCF Per Share

Each share generates $0.98 in free cash annually.

$0.98

FCF Yield

BTMDW converts 32.45% of its market value into free cash.

32.45%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

2.38

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.008

vs 25 benchmark

P/B Ratio

Price to book value ratio

-1.10

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.48

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-1.88

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.22

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.35

vs 25 benchmark

ROA

Return on assets percentage

0.25

vs 25 benchmark

ROCE

Return on capital employed

0.57

vs 25 benchmark

How BTMDW Stacks Against Its Sector Peers

MetricBTMDW ValueSector AveragePerformance
P/E Ratio2.3829.43 Better (Cheaper)
ROE-35.31%684.00% Weak
Net Margin14.07%-45067.00% (disorted) Strong
Debt/Equity-1.880.43 Strong (Low Leverage)
Current Ratio1.224.07 Neutral
ROA25.13%-17158.00% (disorted) Strong

BTMDW outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews biote Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ